How effective is Lifitegrast?

Lifitegrast (Lifitegrast) is a drug used to treat moderate to severe dry eye in adults, especially those who have not responded well to artificial tears. The drug is available as eye drops under the brand name Xiidra and contains the active ingredient lifitegrast.

The pathogenesis of dry eye disease is closely related to T cells in the immune system. These cells play an important role in the body's natural defense system, and their abnormal activity may lead to increased eye inflammation, leading to dry eye syndrome. Ritalast inhibits T cell activity by blocking the interaction between LFA-1 and ICAM-1. This mechanism of action is designed to reduce immune system activation, thereby alleviating dry eye symptoms and associated inflammation.

According to the results of clinical studies, the therapeutic effect of Ritalast has been verified. Two major clinical trials involving a total of 1,429 adults with dry eye syndrome compared ritasilast with an excipient that contained no active ingredient. The effectiveness of these studies was primarily measured by the extent of corneal damage and the severity of patient symptoms, including eye dryness and discomfort.

The study results showed that patients treated with Ritalast experienced significant improvements in corneal damage and symptom relief compared with vehicle. Patients reported a reduction in symptoms, demonstrating the effectiveness of ritasilast in the treatment of dry eye syndrome. At the same time, the safety of Ritalast has also been recognized to a certain extent. Common adverse reactions include eye burning and discomfort, but most patients can tolerate it.

In short, as a new drug for the treatment of dry eye disease, Ritalast can effectively reduce the symptoms of dry eye patients through a special mechanism of action, and has shown good efficacy in clinical trials. This provides patients with a new treatment option, especially when traditional artificial tears are not effective.

Reference materials:https://go.drugbank.com/drugs/DB11611